Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Share-based Compensation (2018 - 2025)

TELA Bio (TELA) has 8 years of Share-based Compensation data on record, last reported at $955000.0 in Q3 2025.

  • For Q3 2025, Share-based Compensation fell 11.66% year-over-year to $955000.0; the TTM value through Sep 2025 reached $4.1 million, down 9.77%, while the annual FY2024 figure was $4.4 million, 13.31% down from the prior year.
  • Share-based Compensation reached $955000.0 in Q3 2025 per TELA's latest filing, down from $985000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.4 million in Q2 2021 and bottomed at $694000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $1.1 million, with a median of $1.0 million recorded in 2025.
  • Peak YoY movement for Share-based Compensation: surged 185.83% in 2021, then decreased 27.62% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $822000.0 in 2021, then rose by 26.4% to $1.0 million in 2022, then increased by 19.44% to $1.2 million in 2023, then decreased by 12.25% to $1.1 million in 2024, then decreased by 12.3% to $955000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $955000.0 in Q3 2025, $985000.0 in Q2 2025, and $1.0 million in Q1 2025.